Recovery for Replimune: Accelerated Approval for Cancer Drug Twice Spurned by FDA
Frank Vinluan / medcitynews - Replimune went from an FDA rejection to a resubmission, a positive advisory committee vote, and finally an accelerated regulatory approval for advanced melanoma — all in less than four months. The FDA nod for Replimune’s oncolytic viral therapy, Tudriqev,…
AI Summary: After two previous turns in the penalty box, the FDA granted accelerated approval to Replimune’s oncolytic immunotherapy Tudriqev (RP1) in combination with nivolumab for advanced melanoma. The decision follows a favorable advisory committee outcome and positions a once-spurned viral-based therapy back into the clinic as a new option for patients with limited choices.
- Clinical community reaction and rollout: experts and training (4)
- Regulatory comeback: FDA approves Tudriqev after two rejections (4)
- Replimune announcements and company leadership reactions (3)
- All Other Stories
Clinical community reaction and rollout: experts and training
Regulatory comeback: FDA approves Tudriqev after two rejections
Replimune announcements and company leadership reactions
All Other Stories
FDA approves Moderna’s mRNA flu vaccine
Ella Jeffries / beckershospitalreview - The FDA has approved Moderna’s mFLUSIVA (mRNA-1010), the first mRNA-based influenza vaccine in the U.S., for the prevention of seasonal influenza in adults ages 50 and older. The decision follows a monthslong regulatory process that included the agency’s …
AI Summary: The FDA has approved Moderna's mRNA flu vaccine, giving the familiar seasonal bug a high-tech reboot. Regulators cleared Moderna’s mRNA formulation for public use, signaling a shift toward next-generation influenza vaccines; rollout details, target groups and supply plans will follow as public health authorities coordinate distribution for the coming flu season.
- FDA's reversal and approval of Moderna mRNA flu shot (3)
- Public health guidance and flu season preparedness (3)
- What mFLUSIVA approval means for policy, coverage and mRNA (3)
FDA's reversal and approval of Moderna mRNA flu shot
Public health guidance and flu season preparedness
What mFLUSIVA approval means for policy, coverage and mRNA
Swallowing faecal capsules reduces peanut allergy in six adults
Alice Klein / newscientist - Altering the gut microbiomes of people with peanut allergy using faeces donated from an allergy-free individual improved their peanut tolerance in a clinical trial
AI Summary: A small human trial showed swallowing fecal microbiota capsules reduced peanut allergy responses in six adults, while parallel animal and mechanistic work implicates bile-acid metabolites in restoring oral tolerance. The findings revive interest in microbiome-based desensitization, though larger trials are required before anyone starts prescribing ‘poop pills’ as routine therapy.
This amino acid may help the body fight tumors and viral infections
medicalxpress - The amino acid arginine helps keep the human body humming, most notably by synthesizing proteins that carry out a range of cellular processes. It's produced by our bodies and found in common high-protein foods. Low levels of arginine are associated with a…
AI Summary: New research implicates the amino acid histidine in modulating immune and tumor biology, suggesting it may enhance anti-tumor responses and antiviral defenses in preclinical studies. Scientists report mechanistic insights that could inform future therapeutic strategies, although translation to patients will require careful testing—because promising mouse data still need to pass the human audit.
Most breastfeeding mothers take medication, but many are making decisions without good information
medicalxpress - When a woman who is breastfeeding develops an infection or a flare of a chronic condition, she faces a decision that sounds simple but rarely is: Should she take the medication to treat her condition?
AI Summary: Surveys and reports show a majority of breastfeeding mothers use medications but often make decisions without adequate, evidence-based clinical guidance. The findings underline gaps in provider counseling and accessible information, urging health systems to improve communication so lactating patients can safely balance treatment needs with breastfeeding goals without needless anxiety.
FDA approves Simtriyo for treating ADHD in children and adults
medicalxpress - The U.S. Food and Drug Administration has approved Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and children 6 years and older weighing ≥20 kg.
AI Summary: The FDA granted approval for Simtriyo to treat attention‑deficit/hyperactivity disorder in children and adults, adding a new prescription option to the ADHD toolkit. Regulators highlighted efficacy and safety data supporting the decision; clinicians and patients will now weigh the drug’s profile against existing therapies as rollout and coverage decisions play out.
CMS to end subsidies for Medicare drug plan premiums
Emily Olsen / healthcaredive - The CMS said the program, which went into effect last year to stabilize Part D premiums and enrollment, isn’t needed anymore. One researcher said some enrollees could see higher premium increases in 2027 as a result.
AI Summary: CMS will terminate its Part D premium stabilization subsidy, a program that helped blunt year-to-year premium swings for Medicare drug plans. The move removes a federal backstop aimed at keeping beneficiaries’ premiums lower, likely pushing costs onto enrollees and plan sponsors while igniting concerns about affordability for seniors and people on fixed incomes.
Prediction Market Betting on Drug Trials and Approvals Sparks Concern About Undermining Research
Rebecca Robbins / nytimes - Prediction markets on Kalshi and Polymarket now let people wager money on drug approvals. Kalshi also plans to allow bets on clinical trial results.
AI Summary: Betting platforms have started offering markets on clinical trial outcomes and FDA decisions, stirring alarms among regulators and researchers. Critics warn these markets could incentivize insider trading, leak-sensitive information, or distort trial conduct, prompting calls for oversight and clearer rules to protect scientific integrity and participant safety — because apparently Wall Street needed another hobby.
Ebola Outbreak Surpasses 3,000 Cases as First Human Vaccine Trial for Rare Bundibugyo Virus Begins
discovermagazine - Learn how a rare Ebola strain has fueled one of the largest outbreaks on record and what the first human vaccine trial could mean for containing the outbreak.
AI Summary: An Ebola outbreak in eastern DR Congo has surpassed 3,000 reported cases and is poised to become the second-largest on record. Authorities have launched the first human vaccine trial targeting the Bundibugyo strain while laboratory tests show stockpiled Ebola vaccines generate antibodies against Bundibugyo, intensifying both response operations and urgent vaccine research.
- Race for a Bundibugyo vaccine: trials and lab progress (5)
- Strained response: strikes, unpaid staff, funding and leadership shake-up (5)
- Surging outbreak: cases, deaths and WHO alarm (7)
- All Other Stories
Race for a Bundibugyo vaccine: trials and lab progress
Strained response: strikes, unpaid staff, funding and leadership shake-up
Surging outbreak: cases, deaths and WHO alarm
All Other Stories
FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma
esmo - Evidence for efficacy is based on the results from the LITESPARK-022 study
AI Summary: Regulators have cleared the combination of belzutifan and pembrolizumab as adjuvant therapy for renal cell carcinoma at high risk of recurrence after nephrectomy. Clinical data showed improved disease‑free survival versus control, offering a new post‑surgery option intended to delay recurrence in patients with residual recurrence risk.
New treatment approach improves survival, reduces recurrence risk in muscle-invasive bladder cancer
medicalxpress - Researchers have found that a combination of enfortumab vedotin and pembrolizumab helps patients with muscle-invasive bladder cancer live longer while reducing the risk that their cancer will return after surgery, according to an international phase 3 cli…
AI Summary: Practice‑changing data and a network meta‑analysis have clarified perioperative strategies for muscle‑invasive bladder cancer, showing that certain neoadjuvant and adjuvant approaches improve survival and reduce recurrence. Recent trial results and comparative evidence are prompting shifts in treatment sequencing for cisplatin‑eligible patients, moving the needle on standards of care.
- Biomarkers and AI Predict Immunotherapy Benefit and Toxicity (4)
- EV‑Pembrolizumab: New Perioperative Standard for Cisplatin‑Eligible MIBC (4)
- Neoadjuvant Combinations and Bladder Preservation Trials (4)
- Network Meta-Analysis Clarifies Optimal Perioperative Strategies (3)
- All Other Stories
Biomarkers and AI Predict Immunotherapy Benefit and Toxicity
EV‑Pembrolizumab: New Perioperative Standard for Cisplatin‑Eligible MIBC
Neoadjuvant Combinations and Bladder Preservation Trials
Network Meta-Analysis Clarifies Optimal Perioperative Strategies
All Other Stories
It has begun: Foxconn amassing army of workers for iPhone 18 Pro assembly
appleinsider - Months ahead of the fall launches, and historically right on time, Apple supply chain partner Foxconn has started to hire a small army of assemblers to build the iPhone 18 Pro.Workers at a Foxconn facility - Image source: FoxconnEach summer, the Apple sup…
AI Summary: Agenus has suspended the BATTMAN clinical trial and announced a follow‑on program called ROBBIN after strategic reassessment, a move that has raised questions about transparency and participant communication. The abrupt pivot highlights tensions between rapid corporate decision‑making and the need to maintain patient trust in oncology research.
US court rules abortion pill restrictions 'unlawful'
medicalxpress - A federal court in Virginia has ruled that restrictions imposed by the U.S. drug regulator on the abortion pill mifepristone are "unlawful" and ordered the Trump administration to reconsider them.
AI Summary: A U.S. court ruled recent restrictions on the abortion pill unlawful, reaffirming FDA regulatory standards and restoring broader access. Industry groups filed briefs backing FDA oversight, warning that legal uncertainty would harm patients and research. The ruling calms access for now while legal and policy debates continue.
Live attenuated vaccines alone or in combination with an adenovirus-based vaccine protect mice lacking IFN-γ against pneumonic plague
Emily K. Hendrix, Jian Sha, Paul B. Kilgore, Blake H. Neil, Atul K. Verma, Heidi Spratt, Ashok K. Ch / science - Science Translational Medicine, Volume 18, Issue 859, July 2026.
AI Summary: Preclinical work shows that a live attenuated vaccine, alone or combined with an adenovirus vector, protected mice lacking key interferon‑gamma defenses from pneumonic plague. The strategy delivered surprising protection in immunocompromised models, suggesting a potential path forward for vaccines designed to work even when classical immune pathways are impaired.
Could this enzyme help remove 'zombie' cells from our tissues?
medicalxpress - Our population is aging. The United Nations reports that by 2050, the number of people age 85 and older on our planet is set to triple. But a longer life span isn't the same as a longer health span (the number of years we spend healthy). Salk Institute sc…
AI Summary: Researchers identified an enzyme that selectively targets senescent “zombie” cells, restoring tissue function in preclinical models and hinting at anti‑aging and therapeutic possibilities. The findings generated excitement for potential disease‑modifying strategies, but experts caution that translating enzyme‑based fixes from mice to humans will require careful safety studies and sober expectations.
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial
Adam D. Cohen / nature - Nature Medicine, Published online: 22 July 2026; doi:10.1038/s41591-026-04522-3In a phase 1 trial, the maximum tolerated dose for an FcRH5-containing bispecific T cell engager was not reached, and there was an encouraging response rate in patients with re…
AI Summary: A phase 1 study of the FcRH5×CD3 bispecific antibody cevostamab reported manageable safety and early signals of activity in relapsed or refractory multiple myeloma. Investigators outlined dosing, adverse events and preliminary responses, setting the stage for larger studies and combination trials as patients and advocates watch for broader access to T‑cell‑engaging therapies.
$10B M&A Deal Pays Off With GSK’s First Lung Cancer Drug Approval
Frank Vinluan / medcitynews - GSK drug Jideytro received FDA approval for treating advanced cases of non-small cell lung cancer driven by ROS1 alterations. This molecule came from Nuvalent, which GSK recently acquired for $10.6 billion. The post $10B M&A Deal Pays Off With GSK’s First…
AI Summary: GSK has won FDA approval for its first lung cancer drug, a gene-targeting therapy that validates the company’s heavy investment and recent M&A strategy. The approval follows pivotal trial evidence of clinical benefit and positions GSK competitively in thoracic oncology, offering a new therapeutic choice for patients with the relevant molecular profile.
D.C. appeals court sides with HHS in 340B drug discount program rebate challenge
fiercehealthcare - The ruling upheld a previous decision that pharma companies cannot impose rebates without HHS Secretary approval.
AI Summary: The D.C. appeals court sided with HHS in a legal challenge over 340B drug discount rebates, affirming federal authority over the program’s rebate models. The ruling preserves HHS policy changes that influence pricing and hospital participation, potentially reshaping pharmacy discounts and provider finances nationwide.
- Appeals court and federal rulings cement HHS 340B authority (3)
- CMS reimbursement shakeup: winners, losers and litigation fallout (3)
- HRSA’s revised 340B rebate pilot and oversight push (3)
Appeals court and federal rulings cement HHS 340B authority
CMS reimbursement shakeup: winners, losers and litigation fallout
HRSA’s revised 340B rebate pilot and oversight push
GLP-1s tied to 37% higher hair loss risk, study finds
Mackenzie Bean / beckershospitalreview - GLP-1 receptor agonists carry a higher risk of hair loss than other diabetes medications, according to a study published July 22 in The BMJ. Researchers at Philadelphia-based Penn Medicine used EHR data to compare adults with Type 2 diabetes who started G…
AI Summary: A series of new analyses tie GLP‑1 diabetes and obesity drugs to a measurable rise in hair loss reports, with varying risk estimates prompting doctors to warn patients and researchers to dig deeper. Clinicians urge monitoring and clearer guidance as these widely used medications shift from metabolic miracles to potential cosmetic headaches.
A Peptide Showdown: F.D.A. Scientists May Clash With R.F.K.’s Agenda
Christina Jewett and Dana G. Smith / nytimes - Agency scientists are advising against allowing widespread use of several peptide injections. Robert F. Kennedy Jr., the health secretary, has said people should be free to experiment.
AI Summary: Federal regulators have zeroed in on a set of peptide injections gaining traction among wellness influencers and endorsed by RFK Jr., prompting internal debates about safety, evidence and regulation. FDA scientists are reviewing the products' claims and potential risks, setting up a clash between celebrity-driven demand and the agency’s evidence-based caution.
- Advisory panel votes to expand compounding despite safety warnings (4)
- FDA review and RFK Jr. clash over influencer‑favored peptides (4)
- Market hype and regulation: guidances, reporting and uncertainty (5)